Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking

Next Previous
X
Search
Trial Profile

Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naltrexone (Primary)
  • Indications Alcoholism; HIV infections
  • Focus Therapeutic Use
  • Acronyms INSPIRE

    • Most Recent Events

    • 16 May 2018 Primary endpoint (Percentage of Those Maintain or Improve to HIV RNA-1 Viral Load Less Then 200 copies/mL-naltrexone versus placebo) has been met, according to results published in the JAIDS:Journal of Acquired Immune Deficiency Syndromes.
    • 16 May 2018 According to results published in the JAIDS:Journal of Acquired Immune Deficiency Syndromes, definition of one of the primary outcomes changed with respect to number of copies from <400 copies/mL to <200 copies/mL as the Department of Health and Human Services HIV treatment guidelines changed their definition of VS to <200 copies/mL as the goal of therapy soon after study initiation.
    • 16 May 2018 Results published in the JAIDS:Journal of Acquired Immune Deficiency Syndromes.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top